Avalo Therapeutics Inc. (AVTX)
$18.36
$-1.35
(-6.85%)
As on 09-Sep-2026 14:35EDT
Market cap
$1,031 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
2.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.2
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-4.7
-
Face value
--
-
Shares outstanding
53,629,989
10 Years Aggregate
CFO
$-218.86 Mln
EBITDA
$-210.85 Mln
Net Profit
$-309.41 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Avalo Therapeutics (AVTX)
| 1.1 | 0.2 | 44.1 | 60.9 | -6.3 | -70.2 | -47.3 |
|
BSE Sensex
| -11.7 | -4.8 | 1.7 | -7.5 | 3.9 | 5.1 | 9.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Avalo Therapeutics (AVTX)
| 144.4 | -18.2 | -99.2 | -35.6 | -51.0 | 66.9 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Avalo Therapeutics (AVTX)
|
18.4 | 1,031.3 | 0.1 | -100.3 | -169,766.1 | -37.7 | -- | 2.3 |
| 83.2 | 12,161.6 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.2 | |
| 263.1 | 17,746.8 | 1,054.4 | 755.9 | 5.7 | -- | 20.9 | 10.5 | |
| 74.2 | 10,109.8 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.5 | |
| 58.0 | 14,621.6 | 2,435.9 | 860.6 | 31.0 | 43 | 18.6 | 7.9 | |
| 107.3 | 12,506.3 | 1,663.7 | 413.6 | 36.3 | 430 | 32.3 | 86.7 | |
| 345.5 | 10,603.5 | 440.5 | 241.5 | 33.4 | 18.7 | 44.9 | 8.1 | |
| 115.6 | 9,761.1 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.5 | |
| 543.1 | 12,501.2 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 23.9 | |
| 582.8 | 16,503.9 | 2,782.3 | 491.5 | 21.1 | 110.1 | 34.7 | 38.2 |
Shareholding Pattern
View DetailsAbout Avalo Therapeutics (AVTX)
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to... interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania. Read more
-
Chairman of the Board, President & CEO
Dr. Garry A. Neil M.D.
-
Chairman of the Board, President & CEO
Dr. Garry A. Neil M.D.
-
Headquarters
Wayne, PA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Avalo Therapeutics (AVTX)
What is the current share price of Avalo Therapeutics Inc (AVTX) Today?
The share price of Avalo Therapeutics Inc (AVTX) is $18.36 (NASDAQ) as of 09-Sep-2026 14:35 EDT. Avalo Therapeutics Inc (AVTX) has given a return of -6.3% in the last 3 years.
What is the current PB & PE ratio of Avalo Therapeutics Inc (AVTX)?
Since, TTM earnings of Avalo Therapeutics Inc (AVTX) is negative, P/E ratio is not available.
The P/B ratio of Avalo Therapeutics Inc (AVTX) is 2.31 times as on 04-Sep-2026, a 57 discount to its peers’ median range of 5.33 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-4.30 |
4.05 |
2024 |
-2.21 |
0.58 |
2023 |
-0.23 |
1.00 |
2022 |
0.00 |
-0.02 |
2021 |
0.00 |
0.00 |
What is the 52 Week High and Low of Avalo Therapeutics Inc (AVTX)?
The 52-week high and low of Avalo Therapeutics Inc (AVTX) are Rs 24.27 and Rs 9.54 as of 10-Sep-2026.
What is the market cap of Avalo Therapeutics Inc (AVTX)?
Avalo Therapeutics Inc (AVTX) has a market capitalisation of $ 1,031 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Avalo Therapeutics Inc (AVTX)?
Before investing in Avalo Therapeutics Inc (AVTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.